Toronto, ON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Easton Pharmaceuticals Inc. (OTC: EAPH) Provides Operational Update on its $2,600,000 CDN framing contract to build approximately
150 homes just outside of Toronto, Ontario.
Easton recently announced that it has entered into a $2,600,000 CDN framing contract and has commenced work on the
framing of approximately 150 homes with a well-known prominent regional builder. The contract is well underway and is expected to
be completed in full in approximately 3 months.
Easton can disclose that it has collected approximately $600,000 CDN in payments to date since operations
commenced, of the $2,600,000 CDN contract. Easton has been presented with another building contract to construct up to 200
residential units in Welland, Ontario, Canada, which it is currently working on finalizing a definitive agreement on.
The Company is currently in the site plan process for its property located in Cobourg, Ontario, which it will
build 42 residential units over the next 3 years, with the first phase approved and ready for 6 units in an existing
mansion.
Easton has been negotiating several lucrative agreements in the pharmaceutical sector, as well as patient
acquisition for a large platform whereby patients can obtain their medicinal marijuana prescriptions online. More details will be
made available once the agreements have been finalized.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical
sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and
currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in
various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico
and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they
have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The
company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable
in the delivery of other drugs. As part of its strategic growth plan, the Company will be entering new lucrative market segments
globally, including Gaming, Real Estate and Hospitality, among others.
For More Information on Easton and Affiliated and Partner Company's Visit:
http://www.eastonpharmaceuticalsinc.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private
Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive",
"anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional
expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject
to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could
differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals
may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the
company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing,
government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial
reports and filings.
CONTACT INFORMATION Evan Karras / CEO / President Tel: 647.362.5700 Email: eastonpharma@protonmail.com
